Clinical Trials Directory

Trials / Unknown

UnknownNCT04923243

The Neuro-epigenetics Biomarkers of Postoperative Delirium in Elderly Patients Undergoing Hip/Knee Replacement

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Zhongnan Hospital · Academic / Other
Sex
All
Age
65 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Introduction: Postoperative delirium (POD), an acute, transient, fluctuating disturbance in attention, cognition, and level of consciousness, is a common (15-53%) postoperative complication, and it is associated with longer hospital stays, worse functional outcomes, higher healthcare costs, and increased mortality. However, at the current time, effective prevention and treatment are not only hampered by lack of knowledge about the neuropathogenesis of POD but also by a lack of biomarkers that could predict individual risk and assess diagnosis and severity of POD. Recent studies have focused on inflammatory markers (IL-1, IL-6, IL-8, IL-10, CRP), Alzheimer's disease-related factors (Tau, Aβ40/42), and nerve injury factors (S100β, NSE), but failed to establishing causality between these markers and POD. Furthermore, these results were contradictory. Previous study of the investigators found that the dysregulation of preoperative microRNA (miR)-146a and miR-181c in cerebrospinal fluid (CSF) and serum was associated with the development and severity of POD. Therefore, the investigators hypothesized these neurimmiRs and other neuro-epigenetics biomarkers might participate in the neuropathogenesis of POD. Purpose: Aims to search for neuro-epigenetics biomarkers to predict and diagnose POD.

Detailed description

Method: 1. Study design: This study is a prospective investigation that searches for neuro-epigenetics biomarkers to predict and diagnose POD. 2. Inclusion criteria / Exclusion Criteria Inclusion criteria: Eligible patients were at least 65 years old and were scheduled to have hip/knee replacement. Exclusion Criteria: 1. a past medical history of neurological or clinically evident neurovascular disease (e.g., Alzheimer's disease, other forms of dementia, stroke); 2. Patients diagnosed with malignant or benign tumors; 3. Mini-Mental State Examination (MMSE) scores of 26 or less; 4. American Society of Anesthesiologists (ASA) score \[a global score that assesses the physical status of patients before surgery, ranging from 1 (normal health) to 5 (moribund)\] greater than 3; 5. a history of alcohol abuse and drug dependence; 6. inability to read or severe visual or auditory deficits; 7. unwillingness to comply with the protocol or procedures.

Conditions

Interventions

TypeNameDescription
PROCEDUREhip/knee replacementhip/knee replacement

Timeline

Start date
2021-11-03
Primary completion
2024-05-01
Completion
2024-06-01
First posted
2021-06-11
Last updated
2023-08-01

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04923243. Inclusion in this directory is not an endorsement.